KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Non Operating Income (2017 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Non Operating Income for 9 consecutive years, with -$220.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non Operating Income fell 0.92% year-over-year to -$220.0 million, compared with a TTM value of -$935.0 million through Dec 2025, up 4.69%, and an annual FY2025 reading of -$934.0 million, up 4.79% over the prior year.
  • Non Operating Income was -$220.0 million for Q4 2025 at Teva Pharmaceutical Industries, up from -$225.0 million in the prior quarter.
  • Across five years, Non Operating Income topped out at -$211.0 million in Q2 2022 and bottomed at -$290.0 million in Q1 2021.
  • Average Non Operating Income over 5 years is -$250.4 million, with a median of -$251.0 million recorded in 2022.
  • The sharpest move saw Non Operating Income plummeted 105.98% in 2021, then grew 22.99% in 2022.
  • Year by year, Non Operating Income stood at -$253.0 million in 2021, then increased by 3.16% to -$245.0 million in 2022, then decreased by 1.63% to -$249.0 million in 2023, then grew by 12.45% to -$218.0 million in 2024, then decreased by 0.92% to -$220.0 million in 2025.
  • Business Quant data shows Non Operating Income for TEVA at -$220.0 million in Q4 2025, -$225.0 million in Q1 2025, and -$218.0 million in Q4 2024.